top of page
PARKINSON'S DISEASE
WHAT IS PARKINSON'S DISEASE?
Parkinson’s disease was first described as “shaking palsy” by Dr. James Parkinson in 1817. Parkinson’s disease was initially named “shaking palsy” due to its main characterizing symptoms which are slowed movement, tremors, gait or balance problems, and stiffness of the limbs and body. Parkinson’s disease (PD) is a neurodegenerative disorder that affects the neurons that produce dopamine in an area of the brain known as the substantia nigra. Dopamine is a neurotransmitter that sends messages to the brain to control body movement. The cause of PD is currently unknown, however, theories of causes of PD include genetic factors and environmental factors. Patterns of age, gender and race have been observed, but are not completely understood.
​
RISK FACTORS OF PARKINSON'S DISEASE
-
SEX
A higher incidence of PD has been observed in male patients.
-
AGE
Incidence of Parkinson’s disease increases with age and is commonly seen in patients over the age of 60. Around 4% of Parkinson’s disease incidences occur in patients 40 years and younger.
-
HEREDITY
The chance of inheriting PD increases if one has a close family member with the disease or multiple family members with PD.
-
ENVIRONMENTAL FACTORS
Increased exposure to environmental toxins such as pesticides, herbicides, and fungicides increases the risk of PD. The environmental toxins may act as neurotoxins and break down dopamine-associated neurons.
​
FIVE STAGES OF PARKINSON'S DISEASE
​
This scale was created by Dr. Margaret Hoehn and Dr. Melvin Yahr. It is an arbitrary scale that rates the severity of Parkinson's disease in a patient.
​Stage I
This stage is not diagnosed very often as its characterizing symptoms are often missed. This stage is characterized by unilateral involvement only, usually with minimal or no functional impairment. The patient experiences tremors, slowness, and poor condition in the arm or leg on one side of the body.
Stage II
This stage is characterized by bilateral or midline involvement, without impairment of balance. The patient experiences tremors, slowness, and poor condition in the arm or leg on both sides of the body.
Stage III
Diagnosis is mostly caught in this stage. The patient experiences a loss of balance and the inability to perform rapid, involuntary movements to maintain balance. This stage is characterized by instability of the patient with the feet together and eyes closed. In spite of this, the patient is able to live a normal, independent life.
Stage IV
This stage is characterized as a fully developed, severely disabling disease. The patient is still able to walk around and stand unassisted but, they are not able to live alone and carry out their normal daily activities.
Stage V
This stage is characterized by the confinement of a patient to a bed or wheelchair unless they are aided. The patient may not be able to get out of a chair or bed without help or stand or turn without falling.
​
Approximately 7 million to 10 million people are living with Parkinson’s disease worldwide. To manage PD, patients are encouraged to exercise regularly and engage in daily activities, visit a speech and language pathologist, maintain a balanced diet including foods high in antioxidants and vitamins, take medication that treat motor symptoms, or have a surgical procedure known as Deep Brain Stimulation to reduce the “on-off” motor fluctuations.
NORMAL SIGNALING PATHWAY
Tyrosine can be found in the pre-synaptic neurons of dopaminergic neurons. Tyrosine is an amino acid synthesized by our bodies and also acquired by consumption of foods high in protein. Tyrosine hydroxylase adds a hydroxyl group to tyrosine to produce L-DOPA which is another amino acid. A carboxyl group is then removed from L-DOPA by action of DOPA decarboxylase. The resulting molecule is the neurotransmitter, Dopamine.
​
Upon dopamine's release, it becomes bound to D1- and D2-type dopamine receptors in the post-synaptic neuron. D1-type receptors function via actions of a G-coupled protein receptor (GCPR) (REF). When dopamine binds to D1-type receptors, it activates the G-protein signaling GTP to bind to the G-alpha subunit. The activated G-alpha subunit stimulates the activation of adenylyl cyclase which catalyzes the formation of a secondary messenger, cAMP. cAMP then activates Protein Kinase A (PKA) which phosphorylates three transcription factors included in the cAMP response element binding protein family (CREB, CREM, and ATF). Phosphorylation of these transcription factors leads to physiological effects such as excitation of nerve cells responsible for motor control, motivation, and reward.
​
CDK5 + DARPP-32
​
D2
PARKINSON SIGNALING PATHWAY
​
Signaling Pathway Dysregulation and Symptom Correlation
​
SLOWED MOVEMENT
The basal ganglia is a region of the brain that contains
​
​
​
​
BALANCE PROBLEMS
​
​
​
TREMORS
​
​
​
STIFFNESS OF LIMBS
​
​
​
LIFE WITH PARKINSON'S DISEASE
Therapeutic Measures for treating Parkinson's Disease
​
Side Effects of Therapeutic Measures
References
1. Bibb, J. A. (2005). Decoding dopamine signaling. Cell, 122(2), 153-155. 10.1016/j.cell.2005.07.011 Retrieved from http://www.sciencedirect.com/science/article/pii/S009286740500704X
2. Dopamine Signaling in Parkinson's Disease Interactive Pathway. (n.d.). Retrieved from https://www.cellsignal.com/contents/science-cst-pathways-neuroscience/dopamine-signaling-in-parkinson-s-disease-interactive-pathway/pathways-park
3. Juárez Olguín, H., Calderón Guzmán, D., Hernández García, E. & Barragán Mejía, G. (2016). The role of dopamine and its dysfunction as a consequence of oxidative stress. Retrieved from https://www.hindawi.com/journals/omcl/2016/9730467/
​
bottom of page